Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

In Psoriasis, Risankizumab Outperforms Adalimumab

Key clinical point: IL-23 targeting antibody shows greater efficacy than TNF-alpha inhibiting antibody.

Major finding: Risankizumab more often led to 90% improvement in PASI (72% versus 47%).

Study details: Randomized, phase 3 trial involving 605 patients with psoriasis.

Disclosures: The study received funding and support from Boehringer Ingelheim and AbbVie. Dr. Lebwohl has consulted for consultant for Allergan, Almirall, Arcutis, Avotres, Birch Biomed, Boehringer Ingelheim, Bristol-Myers Squibb, Cara, Castle Biosciences, Dermavant, Encore, Inozyme, LEO Pharma, Meiji, Menlo, Mitsubishi Pharma, Neuroderm Ltd, Pfizer, Promius, Dr Reddy, Theravance Biopharma, and Verrica.

Citation:

Reich K, et al. Lancet 2019, July 4.